Serosurvey for Japanese encephalitis virus antibodies following an outbreak in an immunologically naïve population, Victoria, 2022: a cross‐sectional study
Medical Journal of Australia · 2024
DOI: 10.5694/mja2.52344 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Journal of Australia, 2024. Verfasst von Madeleine J Marsland und 22 weiteren Autor:innen. Beteiligte Einrichtung: Victorian Department of Health, Melbourne, VIC, Australia. Hauptthemen laut MEDLINE: Encephalitis Virus, Japanese, Encephalitis, Japanese, Antibodies, Viral, Disease Outbreaks. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
To investigate the distribution and prevalence of Japanese encephalitis virus (JEV) antibody (as evidence of past infection) in northern Victoria following the 2022 Japanese encephalitis outbreak, seeking to identify groups of people at particular risk of infection; to investigate the distribution and prevalence of antibodies to two related flaviviruses, Murray Valley encephalitis virus (MVEV) and West Nile virus Kunjin subtype (KUNV). Study design Cross‐sectional serosurvey (part of a national JEV serosurveillance program).
Setting
Three northern Victorian local public health units (Ovens Murray, Goulburn Valley, Loddon Mallee), 8 August – 1 December 2022.
Participants
People opportunistically recruited at pathology collection centres and by targeted recruitment through community outreach and advertisements. People vaccinated against or who had been diagnosed with Japanese encephalitis were ineligible for participation, as were those born in countries where JEV is endemic. Main outcome measures Seroprevalence of JEV IgG antibody, overall and by selected factors of interest (occupations, water body exposure, recreational activities and locations, exposure to animals, protective measures).
Results
813 participants were recruited (median age, 59 years [interquartile range, 42–69 years]; 496 female [61%]); 27 were JEV IgG‐seropositive (3.3%; 95% confidence interval [CI], 2.2–4.8%) (median age, 73 years [interquartile range, 63–78 years]; 13 female [48%]); none were IgM‐seropositive. JEV IgG‐seropositive participants were identified at all recruitment locations, including those without identified cases of Japanese encephalitis. The only risk factors associated with JEV IgG‐seropositivity were age (per year: prevalence odds ratio [POR], 1.07; 95% CI, 1.03–1.10) and exposure to feral pigs (POR, 21; 95% CI, 1.7–190). The seroprevalence of antibody to MVEV was 3.0% (95% CI, 1.9–4.5%; 23 of 760 participants), and of KUNV antibody 3.3% (95% CI, 2.1–4.8%; 25 of 761).
Conclusions
People living in northern Victoria are vulnerable to future JEV infection, but few risk factors are consistently associated with infection. Additional prevention strategies, including expanding vaccine eligibility, may be required to protect people in this region from Japanese encephalitis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Victorian Department of Health, Melbourne, VIC, Australia.
- National Centre for Epidemiology and Population Health, Australian National University, Canberra, ACT.
- Albury Wodonga Health, Wodonga, NSW.
- Goulburn Valley Health, Shepparton, VIC.
- Victorian Infectious Diseases Reference Laboratory, Doherty Institute for Infection and Immunity, Royal Melbourne Hospital, Melbourne, VIC.
- National Centre for Immunisation Research and Surveillance, Sydney Children's Hospitals Network, Sydney, NSW.
ORCID-Profile: Madeleine J Marsland, Tilda N Thomson, Deborah A Williamson, Archana Koirala, Kristine Macartney, Anna Glynn-Robinson
Zitieren
APA
Marsland, M. J., Thomson, T. N., O'Brien, H. M., Peach, E., Bellette, J., Humphreys, N., McKeon, C. A., Cross, W., Moso, M. A., Batty, M., Nicholson, S., Karapanagiotidis, T., Lim, C. K., Williamson, D. A., Winkler, N., Koirala, A., Macartney, K., Glynn-Robinson, A., Stewart, T., …, & Friedman, N. D. (2024). Serosurvey for Japanese encephalitis virus antibodies following an outbreak in an immunologically naïve population, Victoria, 2022: a cross‐sectional study. Medical Journal of Australia. https://doi.org/10.5694/mja2.52344
Vancouver
Marsland MJ, Thomson TN, O'Brien HM, Peach E, Bellette J, Humphreys N, et al. Serosurvey for Japanese encephalitis virus antibodies following an outbreak in an immunologically naïve population, Victoria, 2022: a cross‐sectional study. Medical Journal of Australia. 2024. doi:10.5694/mja2.52344
BibTeX
@article{Marsland2024,
author = {Marsland, Madeleine J and Thomson, Tilda N and O'Brien, Helen M and Peach, Elizabeth and Bellette, Jody and Humphreys, Nicole and McKeon, Clare-Anne and Cross, William and Moso, Michael A and Batty, Mitchell and Nicholson, Suellen and Karapanagiotidis, Theo and Lim, Chuan Kok and Williamson, Deborah A and Winkler, Noni and Koirala, Archana and Macartney, Kristine and Glynn-Robinson, Anna and Stewart, Tony and Minko, Corinna and Snow, Kathryn J and Black, Jim and Friedman, N Deborah},
title = {Serosurvey for Japanese encephalitis virus antibodies following an outbreak in an immunologically naïve population, Victoria, 2022: a cross‐sectional study},
journal = {Medical Journal of Australia},
year = {2024},
doi = {10.5694/mja2.52344}
}
EUVIMED